Elevance Health, Inc. (NYSE:ELV) is highlighted as one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. Analyst Lance Wilkes maintained a Buy rating on ELV with a $585.00 price target. Operating revenue for fiscal Q1 2025 increased by 15.4% to $48.8 billion, with an adjusted operating gain of $3.3 billion.

The company reaffirmed its fiscal year 2025 adjusted diluted EPS range of $34.15 to $34.85. Elevance Health, Inc. returned $1.3 billion of capital to shareholders in the quarter. The company offers telehealth services and conducted over 800,000 virtual visits in 2023.

Elevance Health, Inc. operates through various segments, including Health Benefits, CarelonRx, and Carelon Services. The company provides health plans, pharmacy services, and integrated healthcare-related services. While ELV shows investment potential, other AI stocks may offer greater upside potential and less downside risk.

For more stock insights, check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now” on Insider Monkey. This article is not promotional and is originally published on Insider Monkey.

Read more at Yahoo Finance: Bernstein Maintains a Buy on Elevance Health (ELV), Sets a $585 PT